Intermountain Healthcare will utilise PierianDx for next-generation sequencing (NGS) variant analysis and reporting services to help explore new targeted therapies and provide potential clinical trial opportunities for patients with cancer.
PierianDx CEO Michael Sanderson said: “We are thrilled that Intermountain Healthcare has joined our rapidly expanding partner network.
“Intermountain Healthcare is widely known as a leader in precision medicine and we look forward to continued collaboration opportunities.”
Under the partnership, PierianDx provides a SaaS platform and Clinical Genomics Workspace (CGW), an integrated workspace for genomic analytics, classification, interpretation and reporting.
It also provides the clinical software for informatics, interpretation and reporting of NGS data to Intermountain Healthcare.
Intermountain Healthcare can access the genomic data within CGW’s knowledgebase through PierianDx’s customer network.
CGW comprises millions of biomedical findings driven by public and highly curated sources.
Using PierianDx’ clinical genomics solution, Intermountain Healthcare joins other leading diagnostic labs and health systems.
PierianDx’s CGW offers complete informatics, genomic interpretation, and reporting workflow support for cancer and germline molecular diagnostic testing applications.
Established in 2014, PierianDx is engaged in advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems and laboratories across the world.
CAP and CLIA clinical genomics technologies of the company deliver the most integrated approach across the clinical care spectrum.
Intermountain Precision Genomics targets treatments aimed at delivering quality care at some of the lowest costs in the nation.